Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
C. Ponsioen,E. J. de Groof,64 Authors,P. Morar
2017 · DOI: 10.1016/S2468-1253(17)30248-0
The Lancet Gastroenterology and Hepatology · 281 Citations
TLDR
In this randomised controlled, open-label trial, adults with non-stricturing, ileocaecal Crohn's disease, in whom conventional therapy has failed were randomly allocated to have resection or receive infliximab to assess how they affect health-related quality of life.